Gilead Sciences, Inc. (GILD) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Gilead Sciences, Inc. (GILD) scores 4.0 out of 10 as of , computed from its reported financial statements. That reads as mixed quality. The reading rests on efficiency, and profitability is what holds it back.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
We cannot judge Gilead Sciences, Inc. yet, because fewer than five years had both a return on capital and a cost of capital we could measure. This is not a “no”.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
On the filings behind it, Gilead Sciences, Inc. earns 4.0 out of 10 for business quality as of October 19, 2026. That is mixed quality on our scale. A mixed reading means the strengths and weaknesses roughly cancel out, and the case for the business depends on which pillars you care about most. The figure is a weighted average of five pillars, each scored from 0 to 10 against sector-aware benchmarks from reported statements.
Set against 212 Healthcare companies, Gilead Sciences, Inc. lands at the 45th percentile, just below the middle of the group. The median across the group is 4.4, and the top quarter begins at 6.0, so Gilead Sciences, Inc. is in line with the typical company here.
Profitability scores 2.4 out of 10, which reads as weak. The median across 210 Healthcare companies is 2.7, so Gilead Sciences, Inc. is in line with its peers on this pillar and ranks at the 47th percentile. Weak profitability means the business converts less of its sales and capital into profit than its peers, which can come from thin pricing power, high costs or a temporary squeeze.
On solvency, Gilead Sciences, Inc. scores 3.4, a weak reading. Its peers have a median of 6.5 across 150 Healthcare companies, which places it well below them, at the 13th percentile. A low reading here is a question about resilience: how long the company could keep paying its obligations if earnings dropped.
Gilead Sciences, Inc.’s growth score is 3.8 out of 10 (weak). Against a median of 4.9 among 107 Healthcare companies, that is below the group and the 39th percentile. Weak growth means revenue and earnings have been flat or shrinking against peers, which can be cyclical or a sign of a market that is maturing.
Gilead Sciences, Inc.’s efficiency score is 5.6 out of 10 (average). Against a median of 6.0 among 200 Healthcare companies, that is in line with the group and the 43rd percentile. Middling efficiency is unremarkable on its own, though improvements here tend to show up in free cash flow first.
On predictability, Gilead Sciences, Inc. scores 5.6, an average reading. Its peers have a median of 3.4 across 207 Healthcare companies, which places it well above them, at the 76th percentile. Middling predictability suggests some volatility in the record, enough to read the other pillars with a little caution.
The profile is uneven. Efficiency leads at 5.6 while profitability trails at 2.4, a gap of 3.2 points, so the overall averages a clear strength against a clear soft spot. An efficiency lead means the operation turns what it has into cash better than it does anything else. A profitability shortfall is the one most worth understanding, since it bears directly on whether the business creates value.
The pillar with the most room to move the score is solvency. If it rose to the median of Healthcare companies, 6.5, Gilead Sciences, Inc.’s overall score would go from 4.0 to about 4.6. All five pillars could be scored, so the overall uses the full set of weights out of 100: profitability 25, solvency 20, growth 20, efficiency 15, predictability 20.
These are the Healthcare companies closest to Gilead Sciences, Inc. in market value. Each has its own page scored on the same five pillars, so the comparison is like for like.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Gilead Sciences, Inc. scores 4.0 out of 10, which reads as mixed quality. Its strongest pillar is efficiency, its weakest is profitability. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Gilead Sciences, Inc. ranks at the 45th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Gilead Sciences, Inc.’s 4.0.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for GILD are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card